JAB-21822

A drug being studied in colorectal cancer trials. It appears in 5 clinical trials.

Oral KRAS G12C

United States Investigational

European Union Investigational

Spain Not available

What it is

JAB-21822 is a KRAS G12C inhibitor designed to target colorectal cancers harboring the specific KRAS G12C mutation. This targeted therapy represents a precision medicine approach for CRC patients whose tumors carry this particular oncogenic mutation. The drug is administered in combination with other agents including JAB-3312, standard chemotherapy with bevacizumab, or cetuximab depending on the treatment protocol.

How it works

JAB-21822 works by selectively binding to and inhibiting the KRAS G12C mutant protein, which drives tumor growth and survival in approximately 3-5% of colorectal cancers. By targeting this specific mutant form of KRAS while sparing the wild-type protein, the drug aims to block downstream signaling pathways that promote cancer cell proliferation and survival.

Molecular targets

KRAS G12C

Common side effects

FatigueNauseaDiarrheaDecreased appetiteSkin rashElevated liver enzymesLow white blood cell countVomiting

Not all are listed, and everyone experiences them differently. If you notice any, tell your care team.

Trials with this drug

2 recruiting

A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation. NCT06008288 Recruiting Phase 2 China Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation NCT05288205 Recruiting Phase 1 China JAB-21822 Combined With Chemotherapy and Bevacizumab in Second-line KRAS G12C CRC NCT06838338 Active, not recruiting Phase 1 China JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation NCT05194995 Active, not recruiting Phase 1 China A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China NCT05009329 Active, not recruiting Phase 1 China

Guides that may help

Written for patients and families, in plain language.

KRAS mutation: what it means for your treatmentAlmost half of colorectal cancers carry a mutation in the KRAS gene. Today the most important consequence is that anti-EGFR…Eating during chemotherapy: what the evidence supports and what it does notThere is no "anti-cancer diet" that improves the outcome of chemotherapy. What is proven is that losing weight and muscle during…Cancer-related fatigue: what actually helpsCancer-related fatigue is the most common symptom during and after treatment, and it is not fixed by sleeping more. Before…

See all guides →